Abstract
Tuberculosis is one of the critical health problems worldwide. The search for ways to improve the results of tuberculosis treatment and overcome drug resistance lies in understanding the pathogenesis of the development of the infectious process. The interferon system, particularly the role of interferon-gamma, has been identified as the main link in the immune response in tuberculosis. The clinical efficacy of interferon-gamma has been studied and evaluated in clinical trials since the end of the last century. There was obtained evidence of the clinical efficacy of interferon-gamma as part of complex therapy. Recent experimental data make it possible to consider interferon-gamma as a promising therapeutic option for the treatment of multidrug-resistant tuberculosis as part of complex therapy worthy of further studies.
Highlights
The problem of resistance of microorganisms to antimicrobial drugs and, issues related to the ineffectiveness of treatment remain one of the most urgent in medicine
This study evaluated the clinical efficacy of IFN-γ in the intensive phase of complex treatment of newly diagnosed patients with destructive pulmonary TB with bacterial excretion
A recent study to assess the effects of IFN-γ on macrophage activity in overcoming multidrug-resistant TB (MDR-TB) drug resistance demonstrated the high efficacy of IFN-γ as an adjuvant therapy for MDR-TB
Summary
The problem of resistance of microorganisms to antimicrobial drugs and, issues related to the ineffectiveness of treatment remain one of the most urgent in medicine. Additional exposure to exogenous IFN-γ can play the role of an inducer of the immune system under conditions of a reduced response to antibiotics and correct the endogenous cytokine deficiency.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
